Global Huntington’s Disease Treatment Market Report (2022 To 2027)
Global Huntington’s disease treatment market, share
Dublin, May 12, 2022 (GLOBE NEWSWIRE) — The “Huntington’s Disease Treatment Market, Size, Share, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis” report has been added to from ResearchAndMarkets.com offer.
The report provides a comprehensive analysis of the global Huntington’s disease treatment industry. The global Huntington’s disease treatment market will reach US$1,458.83 million by 2027.
Huntington’s disease (HD) is an inherited neurodegenerative disease caused by an expansion of a series of repetitive CAG triplets in the huntingtin (HTT) gene on chromosome 4, which results in a protein with an abnormally long polyglutamine sequence. Additionally, HD is part of a larger family of polyglutamine recurrent diseases, all of which are neurodegenerative diseases. It is transmitted in an autosomal dominant mode, so that each child of an affected parent has a 50% chance of developing the disease.
Trends shaping the size of the global Huntington’s disease treatment market:
Globally, the increasing prevalence of rare genetic diseases among the metropolitan population has increased the incidence of Huntington’s disease, major healthcare players such as hospital pharmacies, specialty pharmacies, retail pharmacies and others attempting to discover new medicinal approaches, providing a platform for manufacturers to expand their influence in the global market.
However, due to the global COVID-19, the growth rate of the Huntington’s disease treatment market slowed down between 2019 and 2020. The online pharmacy distribution channel was selling off-label drugs to manage HD symptoms during the pandemic, such as antidepressants, antipsychotics and anticonvulsants. Due to the government-imposed lockdown, clinical trials have been postponed during the COVID-19 pandemic.
Furthermore, the market is expected to grow between 2022 and 2023. As of 2021, most hospitals and clinics globally reported an increase in clinic visits for HD treatment. Ingrezza’s has expanded its label to include chorea associated with Huntington’s disease. Own to the increased incidence of HD in western countries. These are expected to be significant market drivers. According to the analysis, the global Huntington’s disease treatment market size is growing at a CAGR of 23.81% during the period 2021-2027.
Global Huntington’s disease treatment industry was 405.03 million US$ in 2021:
Based on the type of treatment, the symptomatic treatment segment holds a major market share. This growth is due to the availability of symptom management products and the patent protection of these products. Xenazine and Austedo are being evaluated as first-line therapy for chorea related to Huntington’s disease. R&D of potential product candidates for the management of symptoms of Huntington’s disease may contribute to the growth of the segment. In October 2021, the US FDA approved orphan drug designation for SOM BIOTECH’s drug SOM3355 to treat chorea associated with Huntington’s disease. As a result, the product has a 7-year exclusivity after US FDA approval.
Geographically, North America holds the dominant market in the Huntington’s disease treatment market:
In North America, there is a massive demand for the treatment of Huntington’s disease due to the increased burden of the disease, advances in technology, increased healthcare expenditures, proactive government initiatives, and increased awareness among patients to treatment products for Huntington’s disease.
Likewise, in Asia-Pacific, the Huntington’s disease treatment market is expected to witness significant growth in the coming year owing to untapped potential, increased product penetration and increasing preponderance of the disease in emerging countries during the forecast period. An increasing number of initiatives undertaken by governments to improve the health status of the population is expected to drive the growth of the HD treatment market in the region.
Key Players and Market Share Information:
Key players such as Pfizer Inc, Bausch Health Cos, Dr. Reddy’s Laboratories, H Lundbeck, Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Limited, Lupine Ltd. and Alnylam Pharmaceuticals are contributing to the development of the market by adopting various strategies such as new product launches and partnerships to obtain higher market revenue.
Main topics covered:
1. Introduction
2. Research and methodology
3. Executive Summary
4. Market dynamics
4.1 Drivers of growth
4.2 Challenges
5. Global Huntington’s Disease Treatment Market
6. Global Huntington’s Disease Treatment Market – Share Analysis
6.1 By type of treatment
6.2 By drug type
6.3 By the end user
6.4 By region
7. Global Huntington’s Disease Treatment Market – By Treatment Type
7.1 Symptomatic therapy
7.2 Disease-modifying therapy
8. Global Huntington’s Disease Treatment Market – By Drug Type
8.1 Antidopaminergic
8.2 Anticonvulsants
8.3 Antipsychotics
8.4 Antidepressants
9. Global Huntington’s Disease Treatment Market – By End User
9.1 Hospital pharmacies
9.2 Specialty pharmacies
9.3 Retail pharmacies
9.4 Others
10. Global Huntington’s Disease Treatment Market – By Region
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Latin America
10.5 Middle East and Africa
11. Carriers five forces
11.1 Bargaining power of buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of competition
11.4 Threat of new entrants
11.5 Threat of Substitutes
12. Main actors
12.1 Pfizer Inc.
12.1.1 Overview
12.1.2 Recent Development
12.1.3 Revenue
12.2 Bausch Health Cos
12.2.1 Presentation
12.2.2 Recent Development
12.2.3 Revenue
12.3 Dr. Reddy’s Laboratories
12.3.1 Overview
12.3.2 Recent Development
12.3.3 Revenue
12.4 PM Lundbeck
12.4.1 Overview
12.4.2 Recent Development
12.4.3 Recipes
12.5 Hikma Pharmaceuticals Plc
12.5.1 Overview
12.5.2 Recent Development
12.5.3 Recipes
12.6 Sun Pharmaceutical Industries Limited
12.6.1 Preview
12.6.2 Recent Development
12.6.3 Income
12.7 Lupine Ltd.
12.7.1 Presentation
12.7.2 Recent Development
12.7.3 Recipes
12.8 Alnylam Pharmaceuticals
12.8.1 Presentation
12.8.2 Recent Development
12.8.3 Recipes
For more information on this report, visit https://www.researchandmarkets.com/r/dezurb
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
